AbCellera Biologics (NASDAQ:ABCL) Announces Quarterly Earnings Results

by · The Markets Daily

AbCellera Biologics (NASDAQ:ABCL – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.13, Zacks reports. AbCellera Biologics had a negative return on equity of 17.21% and a negative net margin of 493.42%.

Here are the key takeaways from AbCellera Biologics’ conference call:

  • AbCellera says its transition to a vertically integrated clinical‑stage biotech is complete, having finished platform investments and its clinical manufacturing facility, and it reports approximately $700 million in available liquidity to fund pipeline execution.
  • Lead program ABCL635 is in a randomized, double‑blind Phase 2 with a pivotal readout expected in Q3 2026 that management views as highly de‑risking and capable of supporting blockbuster potential if it matches or exceeds competitors on efficacy, safety, and once‑monthly dosing — though uncertainty about hot‑flash biology remains.
  • ABCL575 (OX40 ligand) is in Phase 1 and management maintains conviction in the class and its combination potential despite recent external safety signals (Kaposi’s sarcoma), with a Phase 1 readout targeted by year‑end 2026.
  • Two additional internal candidates, ABCL688 (autoimmunity) and ABCL386 (oncology), are in IND‑enabling activities with plans to file INDs/CTAs and start Phase 1/2 studies in 2027, and the company expects to nominate another development candidate in H1 2026.
  • 2025 revenue rose to $75 million (including a $36 million patent‑settlement benefit), R&D spend increased to $187 million and net loss was $146 million, but management says cash, marketable securities and committed government funding provide a multi‑year runway to advance the internal pipeline.

AbCellera Biologics Stock Up 6.9%

Shares of ABCL traded up $0.21 during mid-day trading on Tuesday, reaching $3.24. The company had a trading volume of 5,297,217 shares, compared to its average volume of 4,588,292. The stock has a 50 day moving average of $3.65 and a two-hundred day moving average of $4.24. The stock has a market capitalization of $969.85 million, a P/E ratio of -5.68 and a beta of 0.80. AbCellera Biologics has a 52-week low of $1.89 and a 52-week high of $6.51.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ABCL shares. Leerink Partners downgraded shares of AbCellera Biologics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 7th. Wall Street Zen upgraded shares of AbCellera Biologics from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AbCellera Biologics in a report on Wednesday, January 21st. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $7.75.

Check Out Our Latest Stock Analysis on ABCL

Institutional Investors Weigh In On AbCellera Biologics

A number of institutional investors have recently added to or reduced their stakes in the stock. Invesco Ltd. grew its holdings in shares of AbCellera Biologics by 53.7% during the 2nd quarter. Invesco Ltd. now owns 37,112 shares of the company’s stock worth $127,000 after purchasing an additional 12,966 shares during the period. nVerses Capital LLC purchased a new position in AbCellera Biologics during the fourth quarter worth about $121,000. Advisory Services Network LLC increased its position in shares of AbCellera Biologics by 12.9% during the fourth quarter. Advisory Services Network LLC now owns 29,664 shares of the company’s stock valued at $101,000 after acquiring an additional 3,386 shares during the last quarter. Raymond James Financial Inc. increased its position in shares of AbCellera Biologics by 17.0% during the second quarter. Raymond James Financial Inc. now owns 28,049 shares of the company’s stock valued at $96,000 after acquiring an additional 4,070 shares during the last quarter. Finally, Sherbrooke Park Advisers LLC purchased a new stake in shares of AbCellera Biologics in the 3rd quarter valued at approximately $87,000. Institutional investors and hedge funds own 61.42% of the company’s stock.

About AbCellera Biologics

(Get Free Report)

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.

Recommended Stories